Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2013

Recipharm, Synthonics Partner to Promote Drug Delivery Tech

  • Recipharm Pharmaceutical Development and Synthonics have entered a dual-promotion agreement through which the former firm’s customers will have full access to the latter company’s metal coordination chemistry, which has been shown to improve drug delivery and absorption. Financial terms of the agreement were not disclosed.

    In a statement, Recipharm general manager Maria Lundberg noted: “The application of Synthonics’ chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products.”

    Synthonics’ Ken Slepicka, CEO, added that his firm believes its chemistry will integrate well with Recipharm’s existing solutions.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »